Sam Brusco, Associate Editor01.18.24
Moximed announced that James Leech has joined the company as its new chief financial and strategy officer.
Leech was most recently a founding team member and chief business officer at Palette Life Sciences, a medical device company with focus on interventional urology and radiation oncology. Palette was bought by Teleflex in 2023 for $600 million.
He’s also the founder and managing partner of Warren Point Capital, a medical technology-focused venture firm. He was also previously a senior team member at Back Bay Life Science Advisors, a life science focused banking and strategy consulting firm.
“James adds significant financial and business strategy expertise to our executive team,” said Anton Clifford, Ph.D., founder and CEO of Moximed. “He’s achieved success as a founder, financier, and operator, particularly with companies at a growth stage similar to Moximed. James’ leadership will be instrumental as we continue to scale and grow adoption of the MISHA Knee System.”
“I am excited to join Moximed and help lead the growth of the business,” said Leech. “The MISHA Knee System has a tremendous market opportunity to help millions of knee OA patients before they are ready for joint replacement, and the product is already demonstrating significant patient and surgeon interest early in the commercial launch. I look forward to playing a key role in scaling the business and realizing the full potential of Moximed’s market opportunity.”
Moximed achieved the first commercial cases with the MISHA implantable shock absorber for knee osteoarthritis in September 2023.
Leech was most recently a founding team member and chief business officer at Palette Life Sciences, a medical device company with focus on interventional urology and radiation oncology. Palette was bought by Teleflex in 2023 for $600 million.
He’s also the founder and managing partner of Warren Point Capital, a medical technology-focused venture firm. He was also previously a senior team member at Back Bay Life Science Advisors, a life science focused banking and strategy consulting firm.
“James adds significant financial and business strategy expertise to our executive team,” said Anton Clifford, Ph.D., founder and CEO of Moximed. “He’s achieved success as a founder, financier, and operator, particularly with companies at a growth stage similar to Moximed. James’ leadership will be instrumental as we continue to scale and grow adoption of the MISHA Knee System.”
“I am excited to join Moximed and help lead the growth of the business,” said Leech. “The MISHA Knee System has a tremendous market opportunity to help millions of knee OA patients before they are ready for joint replacement, and the product is already demonstrating significant patient and surgeon interest early in the commercial launch. I look forward to playing a key role in scaling the business and realizing the full potential of Moximed’s market opportunity.”
Moximed achieved the first commercial cases with the MISHA implantable shock absorber for knee osteoarthritis in September 2023.